Key Highlights
- Liminatus Pharma (NASDAQ:LIMN) is indicated at USD 2.98 pre-market on Tuesday, November 10, 2026, up 9.96% from a calculated prior close of USD 2.71, with no catalyst dated November 9 or 10 found.
- A November 3, 2026 8-K disclosed a private Placement of 260,001 shares at USD 2.50 for gross proceeds of USD 650,002.50, expected to close on or about November 20, 2026.
- The October 26 snapshot showed a market Capitalization of USD 4.24 million on 1.34 million shares, with a 52-week range of USD 2.905 to USD 141.50.
- The company reported a net loss of USD 12.52 million and regained Nasdaq bid price compliance on September 29, 2026, after a 1-for-50 reverse split announced in August 2026.
What Moved Liminatus Pharma Pre-Market (+9.96%)
The pre-market price of USD 2.98 is 9.96% above a calculated prior close of USD 2.71, simple arithmetic on the two published numbers, a gain of about USD 0.27. No release dated November 9 or November 10, 2026 was found, so no catalyst is identified. The most recent filing located is the November 3, 2026 8-K, in which the company agreed to sell 260,001 shares at USD 2.50 to a non-U.S. investor. At USD 2.98 the stock trades 19.2% above that placement price, a calculated figure. The 8-K said shares are unregistered and a resale registration is due within 60 days of closing, which is expected on or about November 20, 2026.
Why Reverse-Split Biotechs Move Without News
As general context, a reverse split cuts the share count and raises the quoted price without changing the value of a holding, and many post-split stocks drift lower as holders sell. Liminatus completed a 1-for-50 split after a Nasdaq delisting notice in May 2026, and it regained compliance with the minimum bid rule on September 29, 2026. With only 1.34 million shares outstanding, a few thousand shares can move the price by 10%. Private placements near the market add Supply once resale registrations become effective, which can pressure a rally. Traders also bid up stocks that rebound from a low, and the 52-week low of USD 2.905 sits close to the current quote. A stock that fell 97.9% from its high may also attract short covering when sellers step back, which can produce double-digit moves on tiny Volume with no news at all.
Valuation, Liquidity and Risks for Liminatus Pharma (NASDAQ:LIMN)
The calculated Market Value at USD 2.98 is about USD 4.0 million on 1.34 million shares, against a net loss of USD 12.52 million, so the loss is about three times its market value in a year. The stock is 97.9% below its 52-week high of USD 141.50, a calculated figure that reflects the split adjusted collapse. Volume was only 9,816 shares on October 26, 2026, when the stock closed at USD 3.16, up 7.48%, and fell 10.76% after hours to USD 2.82. Dilution, further Nasdaq deficiency notices and wide pre-market spreads are the main risks, and a Reversal at the 9:30 a.m. ET open is possible. Pre-market sessions run from 4:00 a.m. to 9:30 a.m. ET, when quotes can reflect only a handful of orders. The company must also keep the bid price above USD 1.00 to hold its Nasdaq listing, and a second deficiency would revive delisting risk after the May 2026 notice. Cash was not shown in the published snapshot, so the funding runway cannot be confirmed here. Nothing here suggests the gain will continue.
Where Things Stand
Liminatus Pharma (NASDAQ:LIMN) is up 9.96% pre-market with no catalyst identified in published coverage for November 9 or 10, 2026. The latest known event is the November 3 private placement at USD 2.50 per share. A USD 4.0 million market value and thin volume mean the quote can swing sharply.






Please wait processing your request...